These results suggest that CD153-CpG vaccination improves obesity-induced metabolic disorders, such as glucose tolerance and insulin resistance, and does not have severe adverse events such as weight loss and loss of appetite. This evidence concerns the gene TNFSF8 and obesity due to melanocortin 4 receptor deficiency.